The promise of liquid biopsy is transformative for oncology, offering the ability to monitor cancer in real-time, detect disease earlier, and monitor treatment response without invasive surgical procedures. By analyzing circulating tumor DNA (ctDNA) from a simple blood sample, clinicians can gain critical insights for early detection, Minimal Residual Disease (MRD) monitoring, and treatment selection.
However, the analysis of ctDNA presents significant technical challenges. Labs require highly sensitive tools to detect low-frequency somatic variants and robust methods to interpret complex data, including the increasingly vital field of DNA methylation. Today, SeqOne proudly launches two integrated solutions, SomaLBx and SomaMethyl, to empower molecular laboratories with a powerful, seamless, and provider-agnostic end-to-end workflow for in-house liquid biopsy analysis.
SomaLBx: From ctDNA Noise to Actionable Insights
SomaLBx is SeqOne’s specialized Liquid Biopsy (LBx) analysis workset, engineered to unlock the full potential of ctDNA. It enables highly sensitive, tumor-only somatic variant detection, delivering critical insights for early cancer detection, treatment response monitoring, and recurrence surveillance - all without the need for a matched normal sample.
SomaLBx is a comprehensive solution designed to handle the full spectrum of genomic alterations critical to oncology.
Key Capabilities of SomaLBx:
- Comprehensive Variant Detection: Accurately identifies SNVs, Indels, CNVs, and Translocations/DNA fusions from a single ctDNA sample.
- Optimized Tumor-Only Workflow: A key differentiator, this eliminates the complexity and cost of sequencing a matched normal sample, streamlining the path from sample to report.
- High Sensitivity: Engineered for the challenges of ctDNA. At VAF 0.5%, SomaLBx achieves 100% sensitivity for SNVs & amplifications, and 95% sensitivity for Indels. The pipeline can achieve detection of variant allele frequencies (VAF) down to 0.1%.
- Flexible and Agnostic: SomaLBx is a flexible solution tested with multiple capture-based library prep providers.
SomaMethyl: Unlocking Epigenetic Signatures with Precision
DNA methylation is a transformative biomarker in clinical oncology, providing cancer-specific signatures for early detection, treatment response monitoring, and even identifying a tumor's origin. SomaMethyl is SeqOne's dedicated solution for DNA methylation analysis, designed to run as a separate module that integrates seamlessly with the SeqOne platform.
SomaMethyl provides dedicated tools to turn complex methylation data into clear, interpretable results.
Key Features of SomaMethyl:
- Advanced Visualization: Delivers clear visualization of differentially methylated regions (DMRs) for a given sample.
- Cohort Comparison: Allows for comparison to positive and negative cohorts when available, providing crucial context.
- Detailed Methylation Profiles: Generates comprehensive profiles, including CpG islands coverage and heatmaps, for in-depth analysis.
Why Choose SeqOne for Liquid Biopsy Analysis?
- A Unified Laboratory Ecosystem: Streamline your operations by consolidating Liquid Biopsy (with SomaLBx and SomaMethyl) alongside your other routine testing needs on a single, centralized platform.
- High Sensitivity, Low Friction: Achieve trustworthy results via a tumor-only workflow with high sensitivity and reduced turnaround time (TAT), allowing you to move swiftly from quality-controlled FASTQ data to actionable insights.
- True Agility & Future-Proofing: Beyond broad panel provider and sequencer compatibility, our pipeline adapts effortlessly to custom BED files and specific workflows. Crucially, you can evolve your panel designs without incurring complex lead times or additional costs.
- Accessible & Risk-Free: Experience advanced analytics with zero upfront risk. We offer a flexible pay-as-you-go model and a free trial so you can validate the results on your own data.
Advance Your Liquid Biopsy Analysis with SeqOne
The launch of SomaLBx and SomaMethyl marks a significant step forward, delivering the accuracy and efficiency required to translate ctDNA analysis from research into routine, high-throughput diagnostic care. By providing a robust, in-house solution, SeqOne empowers laboratories to unlock the full promise of liquid biopsy for precision oncology.
About SeqOne
SeqOne is a deep-tech company committed to making personalized medicine a reality. Its AI-powered genomic analysis platform provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analysis of genetic data for applications in oncology, rare and inherited diseases, and infectious diseases. The company now serves a global customer base of healthcare providers and biopharmaceutical companies across more than 30 countries, supported by strong industry partnerships and an expanding presence in the US market.
